(0)
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST)
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that the company s SmartFocus nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression.
Oladele Adebogun M.D. said, I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the num